CoChat

Precision medicine in inflammatory bowel disease: concept, progress and challenges

Open access
Borg-Bartolo, Simon P., Boyapati, Ray Kiran, Satsangi, Jack, Kalla, Rahul · 2020 · F1000Research
Cited by 90

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Crohn’s disease and ulcerative colitis are increasingly prevalent, relapsing and remitting inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their aetiology remains unclear but current evidence shows an increasingly complex pathophysiology broadly centring on the genome, exposome, microbiome and immunome. Our increased understanding of disease pathogenesis is providing an ever-expanding arsenal of therapeutic options, but these can be expensive and patients can lose response or never respond to certain therapies. Therefore, there is now a growing need to personalise therapies on the basis of the underlying disease biology and a desire to shift our approach from “reactive” management driven by disease complications to “proactive” care with an aim to prevent disease sequelae. Precision medicine is the tailoring of medical treatment to the individual patient, encompassing a multitude of data-driven (and multi-omic) approaches to foster accurate clinical decision-making. In IBD, precision medicine would have significant benefits, enabling timely therapy that is both effective and appropriate for the individual. In this review, we summarise some of the key areas of progress towards precision medicine, including predicting disease susceptibility and its course, personalising therapies in IBD and monitoring response to therapy. We also highlight some of the challenges to be overcome in order to deliver this approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.12688/f1000research.20928.1

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 121

  1. J Torres, 2017, Crohn's disease., Lancet., 389, 1741-55, 10.1016/S0140-6736(16)31711-1 · DOI · Paper page
  2. R Ungaro, 2017, Ulcerative colitis., Lancet., 389, 1756-70, 10.1016/S0140-6736(16)32126-2 · DOI · Paper page
  3. N Molodecky, 2012, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review., Gastroenterology., 142, 46-54.e42; quiz e30, 10.1053/j.gastro.2011.10.001 · DOI · Paper page
  4. J Sýkora, 2018, Current global trends in the incidence of pediatric-onset inflammatory bowel disease., World J Gastroenterol., 24, 2741-63, 10.3748/wjg.v24.i25.2741 · DOI · Paper page
  5. B Verstockt, 2018, Genome-wide association studies in Crohn's disease: Past, present and future., Clin Transl Immunology., 7, e1001, 10.1002/cti2.1001 · DOI
  6. J McIlroy, 2018, Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management., Aliment Pharmacol Ther., 47, 26-42, 10.1111/apt.14384 · DOI · Paper page
  7. S Paramsothy, 2018, The current state of the art for biological therapies and new small molecules in inflammatory bowel disease., Mucosal Immunol., 11, 1558-70, 10.1038/s41385-018-0050-3 · DOI
  8. R Weisshof, 2018, Emerging Therapies for Inflammatory Bowel Disease., Adv Ther., 35, 1746-62, 10.1007/s12325-018-0795-9 · DOI · Paper page
  9. B Verstockt, 2018, New treatment options for inflammatory bowel diseases., J Gastroenterol., 53, 585-90, 10.1007/s00535-018-1449-z · DOI · Paper page
  10. S Odes, 2008, How expensive is inflammatory bowel disease? A critical analysis., World J Gastroenterol., 14, 6641-7, 10.3748/wjg.14.6641 · doi:10.3748/wjg.14.6641
  11. J Reinglas, 2018, Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases., World J Gastroenterol., 24, 3567-82, 10.3748/wjg.v24.i32.3567 · DOI
  12. J Burisch, 2013, The burden of inflammatory bowel disease in Europe., J Crohns Colitis., 7, 322-37, 10.1016/j.crohns.2013.01.010 · DOI · Paper page
  13. C Bähler, 2017, Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014., BMC Gastroenterol., 17, 138, 10.1186/s12876-017-0681-y · DOI · Paper page
  14. S Singh, 2018, Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis., J Crohns Colitis., 12, 635-43, 10.1093/ecco-jcc/jjy004 · DOI · Paper page
  15. J Lee, 2012, Predicting the course of IBD: light at the end of the tunnel?, Dig Dis., 30 Suppl 1, 95-9, 10.1159/000341132 · DOI
  16. J Lewis, 2011, The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease., Gastroenterology., 140, 1817-1826.e2, 10.1053/j.gastro.2010.11.058 · DOI · Paper page
  17. E Viennois, 2015, Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine., Inflamm Bowel Dis., 21, 2467-74, 10.1097/MIB.0000000000000444 · DOI
  18. T Stevens, 2018, Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy., Aliment Pharmacol Ther., 48, 1213-31, 10.1111/apt.15033 · DOI
  19. M Orholm, 1999, Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease., Am J Gastroenterol., 94, 3236-8, 10.1111/j.1572-0241.1999.01526.x · DOI
  20. M Spehlmann, 2008, Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study., Inflamm Bowel Dis., 14, 968-76, 10.1002/ibd.20380 · DOI · Paper page
  21. F Moller, 2015, Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011., Am J Gastroenterol., 110, 564-71, 10.1038/ajg.2015.50 · DOI · Paper page
  22. D McGovern, 2015, Genetics of Inflammatory Bowel Diseases., Gastroenterology., 149, 1163-1176.e2, 10.1053/j.gastro.2015.08.001 · DOI · Paper page
  23. G Ramos, 2019, Mechanisms of Disease: Inflammatory Bowel Diseases., Mayo Clin Proc., 94, 155-65, 10.1016/j.mayocp.2018.09.013 · DOI · Paper page
  24. M Zhao, 2019, Impact of Genes and the Environment on the Pathogenesis and Disease Course of Inflammatory Bowel Disease., Dig Dis Sci., 64, 1759-69, 10.1007/s10620-019-05648-w · DOI
  25. L Rigottier-Gois, 2013, Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis., ISME J., 7, 1256-61, 10.1038/ismej.2013.80 · DOI · Paper page
  26. J Park, 2017, IBD immunopathogenesis: A comprehensive review of inflammatory molecules., Autoimmun Rev., 16, 416-26, 10.1016/j.autrev.2017.02.013 · DOI · Paper page
  27. M Rescigno, 2009, Dendritic cells in intestinal homeostasis and disease., J Clin Invest., 119, 2441-50, 10.1172/JCI39134 · DOI · Paper page
  28. B Ahluwalia, 2018, Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies., Scand J Gastroenterol., 53, 379-89, 10.1080/00365521.2018.1447597 · DOI · Paper page
  29. G Ginsburg, 2018, Precision Medicine: From Science To Value., Health Aff (Millwood)., 37, 694-701, 10.1377/hlthaff.2017.1624 · DOI · Paper page
  30. I Solberg, 2009, Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)., Scand J Gastroenterol., 44, 431-40, 10.1080/00365520802600961 · DOI · Paper page
  31. I Solberg, 2007, Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study., Clin Gastroenterol Hepatol., 5, 1430-8, 10.1016/j.cgh.2007.09.002 · DOI · Paper page
  32. L Beaugerie, 2012, Clinical, serological and genetic predictors of inflammatory bowel disease course., World J Gastroenterol., 18, 3806-13, 10.3748/wjg.v18.i29.3806 · DOI
  33. L Peyrin-Biroulet, 2016, Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions., Clin Gastroenterol Hepatol., 14, 348-354.e17, 10.1016/j.cgh.2015.06.001 · DOI · Paper page
  34. M Hong, 2018, Immunochip Meta-Analysis of Inflammatory Bowel Disease Identifies Three Novel Loci and Four Novel Associations in Previously Reported Loci., J Crohns Colitis., 12, 730-41, 10.1093/ecco-jcc/jjy002 · DOI
  35. S Girardin, 2003, Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing., Trends Immunol., 24, 652-8, 10.1016/j.it.2003.10.007 · DOI
  36. S Lesage, 2002, CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease., Am J Hum Genet., 70, 845-57, 10.1086/339432 · DOI · Paper page
  37. A Cuthbert, 2002, The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease., Gastroenterology., 122, 867-74, 10.1053/gast.2002.32415 · DOI · Paper page
  38. I Cleynen, 2013, Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project., Gut., 62, 1556-65, 10.1136/gutjnl-2011-300777 · DOI · Paper page
  39. M Salem, 2015, ATG16L1: A multifunctional susceptibility factor in Crohn disease., Autophagy., 11, 585-94, 10.1080/15548627.2015.1017187 · DOI · Paper page
  40. E Fowler, 2008, ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population: further support for significant disease heterogeneity., Am J Gastroenterol., 103, 2519-26, 10.1111/j.1572-0241.2008.02023.x · DOI
  41. A Latiano, 2009, Polymorphism of the IRGM gene might predispose to fistulizing behavior in Crohn's disease., Am J Gastroenterol., 104, 110-6, 10.1038/ajg.2008.3 · DOI
  42. P Deepak, 2017, Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease., Gastroenterol Clin North Am., 46, 603-26, 10.1016/j.gtc.2017.05.013 · DOI
  43. T Okazaki, 2008, Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions., Inflamm Bowel Dis., 14, 1528-41, 10.1002/ibd.20512 · DOI
  44. I Cleynen, 2016, Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study., Lancet., 387, 156-67, 10.1016/S0140-6736(15)00465-1 · DOI · Paper page
  45. V Pascal, 2017, A microbial signature for Crohn's disease., Gut., 66, 813-22, 10.1136/gutjnl-2016-313235 · DOI · Paper page
  46. E Papa, 2012, Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease., PLoS One., 7, e39242, 10.1371/journal.pone.0039242 · DOI · Paper page
  47. H Somineni, 2019, The Microbiome in Patients With Inflammatory Diseases., Clin Gastroenterol Hepatol., 17, 243-55, 10.1016/j.cgh.2018.08.078 · DOI
  48. P van Rheenen, 2010, Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis., BMJ., 341, c3369, 10.1136/bmj.c3369 · DOI · Paper page
  49. N Kennedy, 2015, Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16–50 years., J Crohns Colitis., 9, 41-9, 10.1016/j.crohns.2014.07.005 · DOI
  50. C Maréchal, 2017, Compliance with the faecal calprotectin test in patients with inflammatory bowel disease., United European Gastroenterol J., 5, 702-7, 10.1177/2050640616686517 · DOI
  51. R Kalla, 2018, Patients’ perceptions of faecal calprotectin testing in inflammatory bowel disease: Results from a prospective multicentre patient-based survey., Scand J Gastroenterol., 53, 1437-42, 10.1080/00365521.2018.1527394 · DOI
  52. A Buisson, 2017, Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease., Inflamm Bowel Dis., 23, 1425-33, 10.1097/MIB.0000000000001140 · DOI · Paper page
  53. M Calafat, 2015, High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling?, Inflamm Bowel Dis., 21, 1072-6, 10.1097/MIB.0000000000000349 · DOI
  54. L Du, 2018, Within-Stool and Within-Day Sample Variability of Fecal Calprotectin in Patients With Inflammatory Bowel Disease: A Prospective Observational Study., J Clin Gastroenterol., 52, 235-40, 10.1097/MCG.0000000000000776 · DOI
  55. J Satsangi, 2016, How to Apply for and Secure EU Funding for Collaborative IBD Research Projects., J Crohns Colitis., 10, 363-70, 10.1093/ecco-jcc/jjv237 · doi:10.1093/ecco-jcc/jjv237
  56. S Vermeire, 2006, Laboratory markers in IBD: useful, magic, or unnecessary toys?, Gut., 55, 426-31, 10.1136/gut.2005.069476 · DOI · Paper page
  57. G Ho, 2009, Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis., Am J Gastroenterol., 104, 673-8
  58. N Kennedy, 2019, Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease., Clin Gastroenterol Hepatol., 17, 2269-2276.e4, 10.1016/j.cgh.2019.02.017 · DOI
  59. R Kalla, 2016, Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases., Am J Gastroenterol., 111, 1796-805, 10.1038/ajg.2016.342 · DOI · Paper page
  60. D Biasci, 2019, A blood-based prognostic biomarker in IBD., Gut., 68, 1386-95, 10.1136/gutjnl-2019-318343 · DOI · Paper page
  61. R Kalla, 2017, Proximity Extension Assay based Proteins Show Immune Cell Specificity and can Diagnose and Predict Outcomes in Inflammatory Bowel Diseases: IBD Character Study., Gastroenterology., 152, S606-S607, 10.1016/S0016-5085(17)32161-3 · doi:10.1016/s0016-5085(17)32161-3
  62. R Kalla, 2017, OC-047 Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – ibd character., Gut., 66, A24-A5, 10.1136/gutjnl-2017-314472.47 · doi:10.1136/gutjnl-2017-314472.47
  63. N Ventham, 2016, Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease., Nat Commun., 7, 13507, 10.1038/ncomms13507 · DOI · Paper page
  64. I Trbojević Akmačić, 2015, Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome., Inflamm Bowel Dis., 21, 1237-47, 10.1097/MIB.0000000000000372 · DOI · Paper page
  65. A Shubhakar, 2019, DOP10 Serum N-glycomic biomarkers predict treatment escalation in inflammatory bowel disease., J Crohns Colitis., 13, S032-S033, 10.1093/ecco-jcc/jjy222.045 · doi:10.1093/ecco-jcc/jjy222.045
  66. L Beaugerie, 2006, Predictors of Crohn's disease., Gastroenterology., 130, 650-6, 10.1053/j.gastro.2005.12.019 · DOI · Paper page
  67. C Loly, 2009, Predictors of severe Crohn's disease., Scand J Gastroenterol., 43, 948-54, 10.1080/00365520801957149 · DOI · Paper page
  68. M Henriksen, 2007, Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study., Am J Gastroenterol., 102, 1955-63, 10.1111/j.1572-0241.2007.01368.x · DOI
  69. F Clerc, 2018, Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases., Gastroenterology., 155, 829-43, 10.1053/j.gastro.2018.05.030 · DOI
  70. F Wolters, 2005, Phenotype at diagnosis predicts recurrence rates in Crohn's disease., Gut., 55, 1124-30, 10.1136/gut.2005.084061 · DOI · Paper page
  71. O Höie, 2007, Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort., Am J Gastroenterol., 102, 1692-701, 10.1111/j.1572-0241.2007.01265.x · DOI · Paper page
  72. E Langholz, 1994, Course of ulcerative colitis: analysis of changes in disease activity over years., Gastroenterology., 107, 3-11, 10.1016/0016-5085(94)90054-x · DOI · Paper page
  73. O Hoie, 2007, Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years., Gastroenterology., 132, 507-5, 10.1053/j.gastro.2006.11.015 · DOI · Paper page
  74. S Kugathasan, 2017, Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study., Lancet., 389, 1710-8, 10.1016/S0140-6736(17)30317-3 · DOI · Paper page
  75. H Sokol, 2008, Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients., Proc Natl Acad Sci U S A., 105, 16731-6, 10.1073/pnas.0804812105 · DOI · Paper page
  76. Y Haberman, 2014, Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature., J Clin Invest., 124, 3617-33, 10.1172/JCI75436 · DOI · Paper page
  77. J Colombel, 2018, Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial., Lancet., 390, 2779-89, 10.1016/S0140-6736(17)32641-7 · DOI · Paper page
  78. S Yang, 2014, A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia., Nat Genet., 46, 1017-20, 10.1038/ng.3060 · DOI · Paper page
  79. T Moriyama, 2016, NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity., Nat Genet., 48, 367-73, 10.1038/ng.3508 · DOI · Paper page
  80. G Walker, 2019, Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease., JAMA., 321, 773-785, 10.1001/jama.2019.0709 · DOI · Paper page
  81. G Heap, 2014, HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants., Nat Genet., 46, 1131-4, 10.1038/ng.3093 · DOI · Paper page
  82. B Warner, 2018, A practical guide to thiopurine prescribing and monitoring in IBD., Frontline Gastroenterol., 9, 10-5, 10.1136/flgastro-2016-100738 · DOI
  83. N de Boer, 2018, Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives., J Crohns Colitis., 12, 610-20, 10.1093/ecco-jcc/jjx181 · DOI
  84. N Mitrev, 2017, Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases., Aliment Pharmacol Ther., 46, 1037-53, 10.1111/apt.14368 · DOI · Paper page
  85. C Steenholdt, 2014, Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial., Gut., 63, 919-27, 10.1136/gutjnl-2013-305279 · DOI · Paper page
  86. N Vande Casteele, 2015, Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease., Gastroenterology., 148, 1320-1329.e3, 10.1053/j.gastro.2015.02.031 · DOI · Paper page
  87. G D’Haens, 2018, Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease., Gastroenterology., 154, 1343-1351.e1, 10.1053/j.gastro.2018.01.004 · DOI · Paper page
  88. A Ricciuto, 2018, Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis., J Crohns Colitis., 12, 1302-15, 10.1093/ecco-jcc/jjy109 · DOI
  89. N West, 2017, Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease., Nat Med., 23, 579-89, 10.1038/nm.4307 · DOI · Paper page
  90. B Verstockt, 2019, Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease., EBioMedicine., 40, 733-42, 10.1016/j.ebiom.2019.01.027 · DOI · Paper page
  91. S Telesco, 2018, Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis., Gastroenterology., 155, 1008-1011.e8, 10.1053/j.gastro.2018.06.077 · DOI
  92. I Morilla, 2019, Colonic MicroRNA Profiles, Identified by a Deep Learning Algorithm, That Predict Responses to Therapy of Patients With Acute Severe Ulcerative Colitis., Clin Gastroenterol Hepatol., 17, 905-13, 10.1016/j.cgh.2018.08.068 · DOI · Paper page
  93. K Kolho, 2015, Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation., Am J Gastroenterol., 110, 921-30, 10.1038/ajg.2015.149 · DOI · Paper page
  94. M Doherty, 2018, Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients., mBio., 9, pii: e02120-17, 10.1128/mBio.02120-17 · DOI · Paper page
  95. N Kennedy, 2019, Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study., Lancet Gastroenterol Hepatol., 4, 341-53, 10.1016/S2468-1253(19)30012-3 · DOI · Paper page
  96. A Sazonovs, 2018, OP013 HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s disease., J Crohns Colitis., 12, S009-S010, 10.1093/ecco-jcc/jjx180.012 · DOI
  97. M Pereira, 2019, A [Glyco]biomarker that Predicts Failure to Standard Therapy in Ulcerative Colitis Patients., J Crohns Colitis., 13, 39-49, 10.1093/ecco-jcc/jjy139 · DOI
  98. Y Haberman, 2019, Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response., Nat Commun., 10, 38, 10.1038/s41467-018-07841-3 · DOI · Paper page
  99. K Cunningham, 2016, Peroxisome Proliferator-activated Receptor-γ Coactivator 1-α (PGC1α) Protects against Experimental Murine Colitis., J Biol Chem., 291, 10184-200, 10.1074/jbc.M115.688812 · DOI
  100. J Martin, 2019, Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy., Cell., 178, 1493-1508.e20, 10.1016/j.cell.2019.08.008 · DOI · Paper page
  101. C Ma, 2018, Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review., Clin Gastroenterol Hepatol., 16, 1407-1419.e22, 10.1016/j.cgh.2018.02.051 · DOI
  102. C Ma, 2018, Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set., Clin Gastroenterol Hepatol., 16, 637-647.e13, 10.1016/j.cgh.2017.08.025 · DOI
  103. L Peyrin-Biroulet, 2015, Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target., Am J Gastroenterol., 110, 1324-38, 10.1038/ajg.2015.233 · DOI · Paper page
  104. C Yzet, 2019, OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: Long-term data from CALM., J Crohns Colitis., 13, S024-S025, 10.1093/ecco-jcc/jjy222.032 · doi:10.1093/ecco-jcc/jjy222.032
  105. A Heida, 2017, Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide., Inflamm Bowel Dis., 23, 894-902, 10.1097/MIB.0000000000001082 · DOI · Paper page
  106. G DʼHaens, 2012, Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease., Inflamm Bowel Dis., 18, 2218-24, 10.1002/ibd.22917 · DOI · Paper page
  107. T Florin, 2006, Clinically active Crohn's disease in the presence of a low C-reactive protein., Scand J Gastroenterol., 41, 306-11, 10.1080/00365520500217118 · DOI
  108. R Boyapati, 2018, Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease., Cochrane Database Syst Rev., 5, CD012540, 10.1002/14651858.CD012540.pub2 · DOI
  109. E Louis, 2012, Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped., Gastroenterology., 142, 63-70.e5, 10.1053/j.gastro.2011.09.034 · DOI · Paper page
  110. N de Suray, 2012, 864 Close Monitoring of CRP and Fecal Calprotectin is Able to Predict Clinical Relapse in Patients With Crohn's Disease in Remission After Infliximab Withdrawal. a Sub-Analysis of the Stori Study., Gastroenterology., 142, S-149, 10.1016/S0016-5085(12)60560-5 · DOI
  111. N Planell, 2017, Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis., J Crohns Colitis., 11, 1335-46, 10.1093/ecco-jcc/jjx091 · DOI
  112. T Dierckx, 2019, GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD., J Crohns Colitis., 13, 389-94, 10.1093/ecco-jcc/jjy162 · DOI
  113. C Dai, 2018, Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis., J Gastroenterol Hepatol., 33, 990-7, 10.1111/jgh.14121 · DOI
  114. S Hiraoka, 2018, Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis., Gut Liver., 12, 142-8, 10.5009/gnl17013 · doi:10.5009/gnl17013
  115. K Shaw, 2016, Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease., Genome Med., 8, 75, 10.1186/s13073-016-0331-y · DOI · Paper page
  116. A Sitapati, 2017, Integrated precision medicine: the role of electronic health records in delivering personalized treatment., Wiley Interdiscip Rev Syst Biol Med., 9, 10.1002/wsbm.1378 · DOI · Paper page
  117. A Waljee, 2017, Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines., J Crohns Colitis., 11, 801-10, 10.1093/ecco-jcc/jjx014 · DOI · Paper page
  118. J Ashton, 2019, Personalising medicine in inflammatory bowel disease-current and future perspectives., Transl Pediatr., 8, 56-69, 10.21037/tp.2018.12.03 · DOI
  119. M Parkes, 2018, PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial., BMJ Open., 8, e026767, 10.1136/bmjopen-2018-026767 · DOI
  120. J Lee, 2017, OC-044 Profile trial: predicting outcomes for crohn’s disease using a molecular biomarker., Gut., 66, A22-A3, 10.1136/gutjnl-2017-314472.44 · DOI
  121. P Shannon, 2003, Cytoscape: a software environment for integrated models of biomolecular interaction networks., Genome Res., 13, 2498-504, 10.1101/gr.1239303 · DOI · Paper page

Cited by

See all 90

Metadata

Authors
Borg-Bartolo, S. P., Boyapati, R. K., Satsangi, J., & Kalla, R.
Venue
F1000Research
Published
2020-01-28
Volume
9
Pages
54
ISSN
2046-1402 (ISSN-L)
OpenAlex
W3003805058
Cited by
90
References
25
FWCI
8.24
Type
journal article
Language
en
Open access
gold
Licence
creativecommons.org/licenses/by/4.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Precision medicine in inflammatory bowel disease: concept, progress and challenges. https://app.cochat.ai/papers/10.12688/f1000research.20928.1
The paper
Borg-Bartolo, S. P., Boyapati, R. K., Satsangi, J., & Kalla, R. (2020). Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Research. https://doi.org/10.12688/f1000research.20928.1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.